We recognize the intrinsic value that research has in the advancement of health, as well as in the continuous improvement of the medical care we provide to our patients; therefore, we present the research that is currently active in our hospital:

• Active psoriatic arthritis

Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of deucravacitinib in participants with active psoriatic arthritis who were not previously treated with biologic disease-modifying antirheumatic drugs.

• Colorectal cancer

Phase 3, randomized study of MRTX849 in combination with Cetuximab versus. Chemotherapy in patients with advanced colorectal cancer with KRAS G12C mutation, with disease progression during or after standard first-line treatment.

• Prostate cancer

Phase 2 study of nivolumab in combination with rucaparib, docetaxel or enzalutamide in men with metastatic castration-resistant prostate cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD).